메뉴 건너뛰기




Volumn 44, Issue 4, 2015, Pages 825-843

Current and Evolving Treatments of Genotype 1 Hepatitis C Virus

Author keywords

Cirrhosis; Hepatitis; Hepatitis C; Ledipasvir antiviral; Simeprevir; Sofosbuvir

Indexed keywords

ALFUZOSIN; AMIODARONE; ASUNAPREVIR PLUS BECLABUVIR PLUS DACLATASVIR; BOCEPREVIR; BUPRENORPHINE; CISAPRIDE; DACLATASVIR; DASABUVIR PLUS OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; DIGOXIN; ELBASVIR PLUS GRAZOPREVIR; FUROSEMIDE; GEMFIBROZIL; GS 9857; LEDIPASVIR; LEDIPASVIR PLUS SOFOSBUVIR; NALOXONE; PEGINTERFERON; PEGINTERFERON ALPHA; PLACEBO; PROTEINASE INHIBITOR; RADALBUVIR; RIBAVIRIN; RIFAMPICIN; SIMEPREVIR; SOFOSBUVIR; SOFOSBUVIR PLUS VELPATASVIR; TAMSULOSIN; TELAPREVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VEDROPREVIR; ANTIVIRUS AGENT;

EID: 84947614518     PISSN: 08898553     EISSN: 15581942     Source Type: Journal    
DOI: 10.1016/j.gtc.2015.06.001     Document Type: Review
Times cited : (16)

References (57)
  • 2
    • 0030039651 scopus 로고    scopus 로고
    • A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon
    • Fattovich G., Giustina G., Favarato S., et al. A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol 1996, 24:38-47.
    • (1996) J Hepatol , vol.24 , pp. 38-47
    • Fattovich, G.1    Giustina, G.2    Favarato, S.3
  • 3
    • 84882252475 scopus 로고    scopus 로고
    • Psychiatric clearance for patients started on interferon-alpha-based therapies
    • Lotrich F.E. Psychiatric clearance for patients started on interferon-alpha-based therapies. Am J Psychiatry 2013, 170:592-597.
    • (2013) Am J Psychiatry , vol.170 , pp. 592-597
    • Lotrich, F.E.1
  • 4
    • 84876740954 scopus 로고    scopus 로고
    • Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial
    • Lawitz E., Lalezari J.P., Hassanein T., et al. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis 2013, 13:401-408.
    • (2013) Lancet Infect Dis , vol.13 , pp. 401-408
    • Lawitz, E.1    Lalezari, J.P.2    Hassanein, T.3
  • 5
    • 79959438789 scopus 로고    scopus 로고
    • Telaprevir for previously untreated chronic hepatitis C virus infection
    • Jacobson I.M., McHutchison J.G., Dusheiko G., ADVANCE Study Team, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011, 364:2405-2416.
    • (2011) N Engl J Med , vol.364 , pp. 2405-2416
    • Jacobson, I.M.1    McHutchison, J.G.2    Dusheiko, G.3    ADVANCE Study, Team4
  • 7
    • 80055076797 scopus 로고    scopus 로고
    • Rapid viral response of once-daily TMC435 plus pegylated interferon/ribavirin in hepatitis C genotype-1 patients: a randomized trial
    • Manns M., Reesink H., Berg T., et al. Rapid viral response of once-daily TMC435 plus pegylated interferon/ribavirin in hepatitis C genotype-1 patients: a randomized trial. Antivir Ther 2011, 16:1021-1033.
    • (2011) Antivir Ther , vol.16 , pp. 1021-1033
    • Manns, M.1    Reesink, H.2    Berg, T.3
  • 8
    • 84877730954 scopus 로고    scopus 로고
    • Sofosbuvir for previously untreated chronic hepatitis C infection
    • Lawitz E., Mangia A., Wyles D., et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013, 368:1878-1887.
    • (2013) N Engl J Med , vol.368 , pp. 1878-1887
    • Lawitz, E.1    Mangia, A.2    Wyles, D.3
  • 9
    • 84871814966 scopus 로고    scopus 로고
    • Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C
    • Gane E.J., Stedman C.A., Hyland R.H., et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 2013, 368:34-44.
    • (2013) N Engl J Med , vol.368 , pp. 34-44
    • Gane, E.J.1    Stedman, C.A.2    Hyland, R.H.3
  • 10
    • 84947614716 scopus 로고    scopus 로고
    • Medications to treat HCV
    • Spach DH, editor. Hepatitis C online. Accessed May 15
    • Spach DH, Kim HN. Medications to treat HCV. In: Spach DH, editor. Hepatitis C online. Available at: . Accessed May 15, 2015. http://www.hepatitisc.uw.edu/page/treatment/drugs.
    • (2015)
    • Spach, D.H.1    Kim, H.N.2
  • 11
    • 84964240184 scopus 로고    scopus 로고
    • Discovery of thienoimidazole-based HCV NS5A inhibitors. Part 1: C2-symmetric inhibitors with diyne and biphenyl linkers
    • Giroux S., Bilimoria D., Cadilhac C., et al. Discovery of thienoimidazole-based HCV NS5A inhibitors. Part 1: C2-symmetric inhibitors with diyne and biphenyl linkers. Bioorg Med Chem Lett 2015, 25:936-939.
    • (2015) Bioorg Med Chem Lett , vol.25 , pp. 936-939
    • Giroux, S.1    Bilimoria, D.2    Cadilhac, C.3
  • 12
    • 84964227488 scopus 로고    scopus 로고
    • Discovery of thienoimidazole-based HCV NS5A inhibitors. Part 2: non-symmetric inhibitors with potent activity against genotype 1a and 1b
    • Giroux S., Bilimoria D., Cadilhac C., et al. Discovery of thienoimidazole-based HCV NS5A inhibitors. Part 2: non-symmetric inhibitors with potent activity against genotype 1a and 1b. Bioorg Med Chem Lett 2015, 25:940-943.
    • (2015) Bioorg Med Chem Lett , vol.25 , pp. 940-943
    • Giroux, S.1    Bilimoria, D.2    Cadilhac, C.3
  • 13
    • 3042547162 scopus 로고    scopus 로고
    • The impact of antiviral treatments on the course of chronic hepatitis C: an evidence-based approach
    • Cammà C., Di Bona D., Craxì A. The impact of antiviral treatments on the course of chronic hepatitis C: an evidence-based approach. Curr Pharm Des 2004, 10:2123-2130.
    • (2004) Curr Pharm Des , vol.10 , pp. 2123-2130
    • Cammà, C.1    Di Bona, D.2    Craxì, A.3
  • 14
    • 77957233758 scopus 로고    scopus 로고
    • Meta-analysis: re-treatment of genotype I hepatitis C nonresponders and relapsers after failing interferon and ribavirin combination therapy
    • Singal A.G., Waljee A.K., Shiffman M., et al. Meta-analysis: re-treatment of genotype I hepatitis C nonresponders and relapsers after failing interferon and ribavirin combination therapy. Aliment Pharmacol Ther 2010, 32:969-983.
    • (2010) Aliment Pharmacol Ther , vol.32 , pp. 969-983
    • Singal, A.G.1    Waljee, A.K.2    Shiffman, M.3
  • 15
    • 84877782905 scopus 로고    scopus 로고
    • Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies
    • Chen J., Florian J., Carter W., et al. Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies. Gastroenterology 2013, 144:1450-1455.
    • (2013) Gastroenterology , vol.144 , pp. 1450-1455
    • Chen, J.1    Florian, J.2    Carter, W.3
  • 16
    • 84931560807 scopus 로고    scopus 로고
    • EASL recommendations on treatment of hepatitis C 2015
    • Electronic address: easloffice@easloffice.eu
    • European Association for the Study of the Liver, Electronic address: easloffice@easloffice.eu EASL recommendations on treatment of hepatitis C 2015. J Hepatol 2015, 10.1016/j.jhep.2015.03.025.
    • (2015) J Hepatol
  • 17
    • 84928898919 scopus 로고    scopus 로고
    • Recommendations for testing, managing, and treating hepatitis C. 2014
    • Updated April 9, 2015. Accessed May 9
    • AASLD/IDSA/IAS-USA. Recommendations for testing, managing, and treating hepatitis C. 2014. Updated April 9, 2015. Available at: . Accessed May 9, 2015. http://hcvguidelines.org.
    • (2015)
  • 18
    • 84878976866 scopus 로고    scopus 로고
    • Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial
    • Kowdley K.V., Lawitz E., Crespo I., et al. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet 2013, 381:2100-2107.
    • (2013) Lancet , vol.381 , pp. 2100-2107
    • Kowdley, K.V.1    Lawitz, E.2    Crespo, I.3
  • 19
    • 84984953152 scopus 로고    scopus 로고
    • Once-daily simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in HCV genotype-1 prior null responders with metavir F0-2: COSMOS study subgroup analysis
    • Sulkowski M.S., Jacobson I.M., Ghalib R., et al. Once-daily simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in HCV genotype-1 prior null responders with metavir F0-2: COSMOS study subgroup analysis. Gastroenterol Hepatol (N Y) 2014, 9:1-18.
    • (2014) Gastroenterol Hepatol (N Y) , vol.9 , pp. 1-18
    • Sulkowski, M.S.1    Jacobson, I.M.2    Ghalib, R.3
  • 20
    • 84911409020 scopus 로고    scopus 로고
    • Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naïve patients: the COSMOS randomised study
    • Lawitz E., Sulkowski M.S., Ghalib R., et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naïve patients: the COSMOS randomised study. Lancet 2014, 384:1756-1765.
    • (2014) Lancet , vol.384 , pp. 1756-1765
    • Lawitz, E.1    Sulkowski, M.S.2    Ghalib, R.3
  • 21
    • 84894297488 scopus 로고    scopus 로고
    • Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection
    • Gane E.J., Stedman C.A., Hyland R.H., et al. Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection. Gastroenterology 2014, 146:736-743.e1.
    • (2014) Gastroenterology , vol.146 , pp. 736-743.e1
    • Gane, E.J.1    Stedman, C.A.2    Hyland, R.H.3
  • 22
    • 84900339263 scopus 로고    scopus 로고
    • Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection
    • Afdhal N., Zeuzem S., Kwo P., ION-1 Investigators, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014, 370:1889-1898.
    • (2014) N Engl J Med , vol.370 , pp. 1889-1898
    • Afdhal, N.1    Zeuzem, S.2    Kwo, P.3    ION-1, Investigators4
  • 23
    • 84900326091 scopus 로고    scopus 로고
    • Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis
    • Kowdley K.V., Gordon S.C., Reddy K.R., ION-3 Investigators, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014, 370:1879-1888.
    • (2014) N Engl J Med , vol.370 , pp. 1879-1888
    • Kowdley, K.V.1    Gordon, S.C.2    Reddy, K.R.3    ION-3, Investigators4
  • 24
    • 84925362379 scopus 로고    scopus 로고
    • Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS)
    • Bourlière M., Bronowicki J.P., de Ledinghen V., et al. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS). Lancet Infect Dis 2015, 15:397-404.
    • (2015) Lancet Infect Dis , vol.15 , pp. 397-404
    • Bourlière, M.1    Bronowicki, J.P.2    de Ledinghen, V.3
  • 25
    • 84899068302 scopus 로고    scopus 로고
    • Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin
    • Feld J.J., Kowdley K.V., Coakley E., et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014, 370:1594-1603.
    • (2014) N Engl J Med , vol.370 , pp. 1594-1603
    • Feld, J.J.1    Kowdley, K.V.2    Coakley, E.3
  • 26
    • 84901044326 scopus 로고    scopus 로고
    • ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV
    • Ferenci P, Bernstein D., Lalezari J., PEARL-III Study, PEARL-IV Study, et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med 2014, 370:1983-1992.
    • (2014) N Engl J Med , vol.370 , pp. 1983-1992
    • Ferenci, P.1    Bernstein, D.2    Lalezari, J.3
  • 27
    • 84901036125 scopus 로고    scopus 로고
    • ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis
    • Poordad F., Hezode C., Trinh R., et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014, 370:1973-1982.
    • (2014) N Engl J Med , vol.370 , pp. 1973-1982
    • Poordad, F.1    Hezode, C.2    Trinh, R.3
  • 28
    • 84892619580 scopus 로고    scopus 로고
    • Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection
    • Sulkowski M.S., Gardiner D.F., Rodriguez-Torres M., AI444040 Study Group, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014, 370:211-221. Available at:. http://www.nejm.org/doi/full/10.1056/NEJMoa1306218.
    • (2014) N Engl J Med , vol.370 , pp. 211-221
    • Sulkowski, M.S.1    Gardiner, D.F.2    Rodriguez-Torres, M.3    AI444040 Study, Group4
  • 29
    • 84879198467 scopus 로고    scopus 로고
    • 1425 Simeprevir (TMC435) with peginterferon/ribavirin for chronic HCV genotype 1 infection in treatment naïve patients: results from QUEST-1, a phase III trial
    • Jacobson I., Dore G.J., Foster G.R., et al. 1425 Simeprevir (TMC435) with peginterferon/ribavirin for chronic HCV genotype 1 infection in treatment naïve patients: results from QUEST-1, a phase III trial. J Hepatol 2013, 58:S574.
    • (2013) J Hepatol , vol.58 , pp. S574
    • Jacobson, I.1    Dore, G.J.2    Foster, G.R.3
  • 30
    • 84879198467 scopus 로고    scopus 로고
    • 1413 Simeprevir (TMC435) with peginterferon/ribavirin for chronic HCV genotype 1 infection in treatment naïve patients: results from QUEST-2, a phase III trial
    • Manns M., Marcellin P., Poordad F.P., et al. 1413 Simeprevir (TMC435) with peginterferon/ribavirin for chronic HCV genotype 1 infection in treatment naïve patients: results from QUEST-2, a phase III trial. J Hepatol 2013, 58:S568.
    • (2013) J Hepatol , vol.58 , pp. S568
    • Manns, M.1    Marcellin, P.2    Poordad, F.P.3
  • 31
    • 84933181408 scopus 로고    scopus 로고
    • Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic HCV genotype 1 infection: analysis of phase 3 ION trials
    • Alqahtani S.A., Afdhal N., Zeuzem S., et al. Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic HCV genotype 1 infection: analysis of phase 3 ION trials. Hepatology 2015, 10.1002/hep.27890.
    • (2015) Hepatology
    • Alqahtani, S.A.1    Afdhal, N.2    Zeuzem, S.3
  • 32
    • 84958599246 scopus 로고    scopus 로고
    • A phase 3, randomised, open-label study to evaluate the efficacy and safety of 12 and 8 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naive and -experienced patients with chronic HCV genotype 1 infection without cirrhosis: OPTIMIST-1
    • Vienna (Austria), April 22-26
    • Kwo P, Gitlin N, Nahass R, et al. A phase 3, randomised, open-label study to evaluate the efficacy and safety of 12 and 8 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naive and -experienced patients with chronic HCV genotype 1 infection without cirrhosis: OPTIMIST-1. Program and abstracts of the 50th Annual Meeting of the European Association for the Study of the Liver. Vienna (Austria), April 22-26, 2015. Abstract LB14. Available at: . https://ilc-congress.eu/scientific-info/abstracts/.
    • (2015) Program and abstracts of the 50th Annual Meeting of the European Association for the Study of the Liver
    • Kwo, P.1    Gitlin, N.2    Nahass, R.3
  • 33
    • 84895736477 scopus 로고    scopus 로고
    • SVR results of a once-daily regimen of simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in cirrhotic and non-cirrhotic HCV genotype 1 treatment-naive and prior null responder patients: the COSMOS study
    • Jacobson I.M., Ghalib R.H., Rodriguez-Torres M., et al. SVR results of a once-daily regimen of simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in cirrhotic and non-cirrhotic HCV genotype 1 treatment-naive and prior null responder patients: the COSMOS study. Hepatology 2013, 58:1379A.
    • (2013) Hepatology , vol.58 , pp. 1379A
    • Jacobson, I.M.1    Ghalib, R.H.2    Rodriguez-Torres, M.3
  • 34
    • 84898669547 scopus 로고    scopus 로고
    • Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection
    • Afdhal N., Reddy K.R., Nelson D.R., et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014, 370:1483-1493. Available at:. http://www.nejm.org/doi/full/10.1056/NEJMoa1316366.
    • (2014) N Engl J Med , vol.370 , pp. 1483-1493
    • Afdhal, N.1    Reddy, K.R.2    Nelson, D.R.3
  • 35
    • 84904647749 scopus 로고    scopus 로고
    • ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection
    • Andreone P., Colombo M.G., Enejosa J.V., et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology 2014, 147:359-365.e1.
    • (2014) Gastroenterology , vol.147 , pp. 359-365.e1
    • Andreone, P.1    Colombo, M.G.2    Enejosa, J.V.3
  • 36
    • 84899106124 scopus 로고    scopus 로고
    • Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin
    • Zeuzem S., Jacobson I.M., Baykai T., et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014, 370:1604-1614. Available at:. http://www.nejm.org/doi/full/10.1056/NEJMoa1401561.
    • (2014) N Engl J Med , vol.370 , pp. 1604-1614
    • Zeuzem, S.1    Jacobson, I.M.2    Baykai, T.3
  • 37
    • 84871487025 scopus 로고    scopus 로고
    • Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis
    • van der Meer A.J., Veldt B.J., Feld J.J., et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012, 308:2584-2593.
    • (2012) JAMA , vol.308 , pp. 2584-2593
    • van der Meer, A.J.1    Veldt, B.J.2    Feld, J.J.3
  • 38
    • 79951704255 scopus 로고    scopus 로고
    • Long-term outcome after antiviral therapy of patients with hepatitis C virus infection and decompensated cirrhosis
    • Iacobellis A., Perri F., Valvano M.R., et al. Long-term outcome after antiviral therapy of patients with hepatitis C virus infection and decompensated cirrhosis. Clin Gastroenterol Hepatol 2011, 9:249-253.
    • (2011) Clin Gastroenterol Hepatol , vol.9 , pp. 249-253
    • Iacobellis, A.1    Perri, F.2    Valvano, M.R.3
  • 42
    • 84943583893 scopus 로고    scopus 로고
    • Daclatasvir, sofosbuvir, and ribavirin combination for HCV patients with advanced cirrhosis or post-transplant recurrence: ALLY-1 phase 3 study
    • Vienna (Austria), April 22-26
    • Poordad F, Schiff ER, Vierling JM, et al. Daclatasvir, sofosbuvir, and ribavirin combination for HCV patients with advanced cirrhosis or post-transplant recurrence: ALLY-1 phase 3 study. Program and abstracts of the 50th Annual Meeting of the European Association for the Study of the Liver. Vienna (Austria), April 22-26, 2015. Abstract L08. Available at: . https://ilc-congress.eu/scientific-info/abstracts/.
    • (2015) Program and abstracts of the 50th Annual Meeting of the European Association for the Study of the Liver
    • Poordad, F.1    Schiff, E.R.2    Vierling, J.M.3
  • 43
    • 84939269033 scopus 로고    scopus 로고
    • A phase 3, open-label, single-arm study to evaluate the efficacy and safety of 12 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naive or -experienced patients with chronic HCV genotype 1 infection and cirrhosis: OPTIMIST-2
    • Vienna (Austria), April 22-26
    • Lawitz E, Matusow G, DeJesus E, et al. A phase 3, open-label, single-arm study to evaluate the efficacy and safety of 12 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naive or -experienced patients with chronic HCV genotype 1 infection and cirrhosis: OPTIMIST-2. Program and abstracts of the 50th Annual Meeting of the European Association for the Study of the Liver. Vienna (Austria), April 22-26, 2015. Abstract LP04. Available at: . https://ilc-congress.eu/scientific-info/abstracts/.
    • (2015) Program and abstracts of the 50th Annual Meeting of the European Association for the Study of the Liver
    • Lawitz, E.1    Matusow, G.2    DeJesus, E.3
  • 44
    • 84973461613 scopus 로고    scopus 로고
    • Safety and efficacy of sofosbuvir-containing regimens in hepatitis C infected patients with reduced renal function: real world experience from HCV-TARGET
    • Vienna (Austria), April 22-26
    • Saxena V, Koraishy FM, Sise M, et al. Safety and efficacy of sofosbuvir-containing regimens in hepatitis C infected patients with reduced renal function: real world experience from HCV-TARGET. Program and abstracts of the 50th Annual Meeting of the European Association for the Study of the Liver. Vienna (Austria), April 22-26, 2015. Abstract LP08. Available at: . https://ilc-congress.eu/scientific-info/abstracts/.
    • (2015) Program and abstracts of the 50th Annual Meeting of the European Association for the Study of the Liver
    • Saxena, V.1    Koraishy, F.M.2    Sise, M.3
  • 45
    • 84929600780 scopus 로고    scopus 로고
    • Ledipasvir-sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens
    • Wyles D., Pockros P., Morelli G., et al. Ledipasvir-sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens. Hepatology 2015, 61(6):1793-1797.
    • (2015) Hepatology , vol.61 , Issue.6 , pp. 1793-1797
    • Wyles, D.1    Pockros, P.2    Morelli, G.3
  • 46
    • 84999899643 scopus 로고    scopus 로고
    • Retreatment of patients who failed 8 or 12 weeks of ledipasvir/sofosbuvir-based regimens with ledipasvir/sofosbuvir for 24 weeks
    • Vienna (Austria), April 22-26
    • Lawitz E, Flamm S, Yang JC, et al. Retreatment of patients who failed 8 or 12 weeks of ledipasvir/sofosbuvir-based regimens with ledipasvir/sofosbuvir for 24 weeks. Program and abstracts of the 50th Annual Meeting of the European Association for the Study of the Liver. Vienna (Austria), April 22-26, 2015. Abstract O005. Available at: . https://ilc-congress.eu/scientific-info/abstracts/.
    • (2015) Program and abstracts of the 50th Annual Meeting of the European Association for the Study of the Liver
    • Lawitz, E.1    Flamm, S.2    Yang, J.C.3
  • 47
    • 84939254831 scopus 로고    scopus 로고
    • Grazoprevir/elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent
    • Forns X., Gordon S.C., Zuckerman E., et al. Grazoprevir/elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent. J Hepatol 2015, 10.1016/j.jhep.2015.04.009.
    • (2015) J Hepatol
    • Forns, X.1    Gordon, S.C.2    Zuckerman, E.3
  • 48
    • 84896700801 scopus 로고    scopus 로고
    • Pattern and associated factors of anti-hepatitis C virus treatment-induced adverse reactions
    • Ravi S., Nasiri-Toosi M., Karimzadeh I., et al. Pattern and associated factors of anti-hepatitis C virus treatment-induced adverse reactions. Expert Opin Drug Saf 2014, 13:277-286.
    • (2014) Expert Opin Drug Saf , vol.13 , pp. 277-286
    • Ravi, S.1    Nasiri-Toosi, M.2    Karimzadeh, I.3
  • 49
    • 84893819990 scopus 로고    scopus 로고
    • What is the future of ribavirin therapy for hepatitis C?
    • Koh C., Liang T.J. What is the future of ribavirin therapy for hepatitis C?. Antivir Res 2014, 104:34-39.
    • (2014) Antivir Res , vol.104 , pp. 34-39
    • Koh, C.1    Liang, T.J.2
  • 50
    • 84947617637 scopus 로고    scopus 로고
    • [package insert]. Whitehouse station (NJ): Merck & Co, Inc
    • Rebetol [package insert]. Whitehouse station (NJ): Merck & Co, Inc; 2014.
    • (2014)
  • 51
    • 84925424553 scopus 로고    scopus 로고
    • Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patient with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial
    • Lawitz E., Gane E., Pearlman B., et al. Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patient with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial. Lancet 2014, 385(9973):1075-1086. Available at:. http://www.jwatch.org/na36381/2014/12/04/promising-all-oral-hcv-regimen-difficult-treat-groups#sthash.upvkVlyJ.dpuf.
    • (2014) Lancet , vol.385 , Issue.9973 , pp. 1075-1086
    • Lawitz, E.1    Gane, E.2    Pearlman, B.3
  • 52
    • 84937064772 scopus 로고    scopus 로고
    • Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic HCV genotype 1, 4, or 6 infection: a randomized trial
    • Zeuzem S., Ghalib R., Reddy K.R., et al. Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic HCV genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med 2015, 10.7326/M15-0785.
    • (2015) Ann Intern Med
    • Zeuzem, S.1    Ghalib, R.2    Reddy, K.R.3
  • 53
    • 84929207643 scopus 로고    scopus 로고
    • Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection
    • Poordad F., Sievert W., Mollison L., UNITY-1 Study Group, et al. Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection. JAMA 2015, 313:1728-1735.
    • (2015) JAMA , vol.313 , pp. 1728-1735
    • Poordad, F.1    Sievert, W.2    Mollison, L.3    UNITY-1 Study, Group4
  • 54
    • 84929208843 scopus 로고    scopus 로고
    • Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis
    • Muir A.J., Poordad F., Lalezari J., et al. Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis. JAMA 2015, 313:1736-1744.
    • (2015) JAMA , vol.313 , pp. 1736-1744
    • Muir, A.J.1    Poordad, F.2    Lalezari, J.3
  • 55
    • 84925607745 scopus 로고    scopus 로고
    • Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study
    • Kohli A., Osinusi A., Sims Z., et al. Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study. Lancet 2015, 385:1107-1113.
    • (2015) Lancet , vol.385 , pp. 1107-1113
    • Kohli, A.1    Osinusi, A.2    Sims, Z.3
  • 56
    • 84971496437 scopus 로고    scopus 로고
    • Safety and efficacy of short-duration treatment with GS-9857 combined with sofosbuvir/GS-5816 in treatment-naive and DAA-experienced genotype 1 patients with and without cirrhosis
    • Vienna (Austria), April 22-26
    • Gane EJ, Hyland RH, Tang Y, et al. Safety and efficacy of short-duration treatment with GS-9857 combined with sofosbuvir/GS-5816 in treatment-naive and DAA-experienced genotype 1 patients with and without cirrhosis. Program and abstracts of the 50th Annual Meeting of the European Association for the Study of the Liver. Vienna (Austria), April 22-26, 2015. Abstract LP03. Available at: . https://ilc-congress.eu/scientific-info/abstracts/.
    • (2015) Program and abstracts of the 50th Annual Meeting of the European Association for the Study of the Liver
    • Gane, E.J.1    Hyland, R.H.2    Tang, Y.3
  • 57
    • 84891543215 scopus 로고    scopus 로고
    • A small-molecule inhibitor of hepatitis C virus infectivity
    • Bush C.O., Pokrovskii M.V., Saito R., et al. A small-molecule inhibitor of hepatitis C virus infectivity. Antimicrob Agents Chemother 2014, 58(1):386-396.
    • (2014) Antimicrob Agents Chemother , vol.58 , Issue.1 , pp. 386-396
    • Bush, C.O.1    Pokrovskii, M.V.2    Saito, R.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.